相关实验视频
Updated: Jun 22, 2026

00:07
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.2K
计算分析表明,来自AsnGTT 3'-tRNA的碎片是乳腺甲状腺癌的潜在生物标志物
Annie N Do1,2, Shruti Magesh1,2, Matthew Uzelac1,2,3
1Research Service, VA San Diego Healthcare System, San Diego, CA 92161, USA.
International journal of molecular sciences
|October 16, 2024
概括
转移RNA衍生碎片 (tRFs) 与癌症有关. 这项研究发现特定的tRFs,包括AsnGTT 3'-tRF,在乳头甲状腺癌 (PTC) 中失调,这表明它们可能是新的生物标志物.
科学领域:
- 分子生物学分子生物学
- 基因组学就是基因组学.
- 在瘤学瘤学.
背景情况:
- 转移RNA衍生碎片 (tRFs) 是小的非编码RNA,涉及到瘤发生.
- 乳头甲状腺癌 (PTC) 的发病率正在上升,突出显示了对新型诊断生物标志物的需求.
- 尽管tRF在基因表达中的调节作用,但tRF作为PTC的生物标志物尚未得到充分研究.
研究的目的:
- 在PTC组织中识别失调的tRFs,这些tRFs可以作为潜在的生物标记者候选物.
- 调查tRFs和PTC中的驱动基因之间的调控关系.
- 探索tRFs作为PTC中转录后调节者的潜力.
主要方法:
- 使用MINTbase v2.0和癌症基因图谱分析PTC初级瘤 (n=511) 和相邻的正常组织 (n=59) 的tRF和基因表达数据.
- 识别失调的tRF和具有抗相关表达模式的驱动基因.
- 基于RNA22的结合亲和度分析,以预测tRF-mRNA相互作用并验证RNA沉默机制.
主要成果:
- 四个tRF在PTC组织中显著失调 (p <0.05),其中AsnGTT 3'-tRF显著上调.
- AsnGTT 3 '-tRF (tRF-30-RY73W0K5KKOV) 显示了对下调 PTC 相关基因的潜在结合亲缘关系:SLC26A4,SLC5A8,DIO2 和 TPO.
- AsnGTT 3'-tRF与这些基因之间的抗相关表达支持转录后调节作用.
结论:
- AsnGTT 3'-tRF在PTC中显著失调,并可能起到后转录调节者的作用.
- 这项研究确定了AsnGTT 3'-tRF作为一个有前途的候选生物标志物用于PTC诊断.
- 对tRF的进一步研究可能会导致针对乳头甲状腺癌的新型诊断和治疗策略.
相关概念视频
Non-LTR Retrotransposons
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

